Navigation Links
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Date:2/6/2012

The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.

* Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.

* The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.

* Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.

* Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.

* Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer..

* The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.

* The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharm
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
2. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
3. KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
4. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
5. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
6. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
7. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
8. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
9. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... put the brakes on motherhood. And for many young women, ... new research suggests. Women in their early 20s appear ... tough economic times. But, according to the new study, that ... 40s and beyond. The findings suggest that higher unemployment ...
(Date:9/30/2014)... "brain tsunamis" in injured patients without opening the ... thanks to pioneering research at the University of ... led by Jed Hartings, PhD, research associate professor ... College of Medicine, has shown that spreading depolarizationselectrical ... tsunami wavescan be measured by the placement of ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Sleep apnea is a potential health ... to a possible culprit behind the disorder: a "fat" tongue. ... deposits are increased in the tongue of obese patients with ... of the Sleep Center at the University of Pennsylvania Medical ... which will publish the findings Oct. 1. Sleep apnea ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling costs ... treat Medicare patients has had no meaningful impact on ... in the Journal of Clinical Oncology published ... chemotherapy to treat colorectal and lung cancers, and did ... those drugs following the implementation of the recent Medicare ...
Breaking Medicine News(10 mins):Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2
... food products. According to a team of University of ... on its viewers, especially university students. , "The transition ... a time for taking on many negative health behaviors ... in physical activity and fruit and vegetable consumption," said ...
... common vaginal infection may make women more susceptible to contracting ... at Chapel Hill School of Public Health researchers have found. ... more than 30,700 women from around the world, showed that ... vaginosis in women of reproductive age were more likely ...
... standardization across ... savings, IRVINE, Calif., July 31 Masimo, ... that Aurora Health Care has completed a system-wide,conversion ... health,care provider with 13 hospitals and more than ...
... support nonprofits in Portland and Seattle that improve health ... ... 31 The Regence Foundation today,announced three grants totaling $195,000 for ... Regence,Foundation is the corporate foundation of The Regence Group and was ...
... and health systems,expert Ann Lion Coleman will join ... project in August 2008. Health Systems 20/20 is ... to strengthen health,systems by using an integrated approach ... to further the use of,life-saving priority health services., ...
... July 31 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... Western,healthcare products and services in the People,s Republic ... its fiscal 2009 first quarter,financial results on Thursday, ... host a conference call at 8:00 am ET ...
Cached Medicine News:Health News:Watching too much TV is causing some university students to pack on the pounds 2Health News:UNC study: Common vaginal infection may increase risk of HIV infection 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 5Health News:Regence Foundation Announces Three Grants Totaling $195,000 2Health News:Ann Lion Coleman Joins Abt Associates to Direct USAID Health Systems 20/20 Project 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 3
... , Standby: A standby switch maintains power to ... 1 s (1 pulse/s) , Tetanus: 100 ... s) , Output Current: Adjustable from 0-70 mA ... (200-us duration) , Indicators: Battery LED (green) indicates ...
... A range of easy to use ... RDG nerve locator, peripheral nerve stimulator, and ... insulating pole, plastic hub, and pencil point ... an inexpensive, practical and easy to use ...
Based on the original MS-1 design the new MS-1B includes low battery detection, FET based output circuitry and enhanced battery compartment....
... for the delivery and monitoring of inhaled ... is a fully integrated, innovative instrument used ... therapy. The INOvent delivery system works in ... machine) to deliver a constant concentration of ...
Medicine Products: